4
Marcus S. Md, Sachdev J, Jeyaraj P. Md +1 more
Abstract- Background: Tamoxifen acts as an estrogen agonist on the female genital tract. The side effect of major concern is endometrial carcinoma. Aim: The aim of this study was to determine the prevalence and significance of endometrial changes in breast cancer patients, receiving tamoxifen and the factors influencing it. Materials and Methods: The cohort comprised of 10 years retrospective group (RG) and one year prospective group (PG) of patients receiving tamoxifen. Transvaginal ultrasonography (TVS) was done at scheduled intervals and fractional curettage was carried out if endometrial stripe thickness (EST) ≥ 15mm. Results: Only 12 (11.6%) patients on tamoxifen therapy developed EST ≥ 15mm. Two (16.66%) patients with suspicious histopathology on fractional curettage underwent TAH+ BSO. Amongst them one patient had adenosarcoma of mixed mullerian